Free Trial

Repligen (NASDAQ:RGEN) Trading Down 3.1% - Should You Sell?

Repligen logo with Medical background

Shares of Repligen Corporation (NASDAQ:RGEN - Get Free Report) fell 3.1% during mid-day trading on Monday . The company traded as low as $120.68 and last traded at $123.56. 123,900 shares changed hands during trading, a decline of 83% from the average session volume of 734,965 shares. The stock had previously closed at $127.52.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on RGEN. HC Wainwright reiterated a "buy" rating and set a $180.00 target price on shares of Repligen in a research report on Monday, May 5th. Evercore ISI began coverage on shares of Repligen in a research report on Tuesday, March 18th. They set an "in-line" rating and a $155.00 target price on the stock. Royal Bank Of Canada reduced their target price on shares of Repligen from $202.00 to $189.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 30th. JPMorgan Chase & Co. reduced their target price on shares of Repligen from $200.00 to $190.00 and set an "overweight" rating on the stock in a research report on Tuesday, April 29th. Finally, Canaccord Genuity Group reduced their target price on shares of Repligen from $170.00 to $150.00 and set a "hold" rating on the stock in a research report on Wednesday, April 16th. Five analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $173.25.

Check Out Our Latest Analysis on Repligen

Repligen Price Performance

The company's fifty day moving average is $128.79 and its two-hundred day moving average is $142.14. The firm has a market capitalization of $6.60 billion, a price-to-earnings ratio of -261.20, a price-to-earnings-growth ratio of 3.37 and a beta of 1.10. The company has a quick ratio of 5.79, a current ratio of 6.79 and a debt-to-equity ratio of 0.27.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, beating the consensus estimate of $0.35 by $0.04. Repligen had a negative net margin of 3.93% and a positive return on equity of 4.53%. The business had revenue of $169.17 million for the quarter, compared to analyst estimates of $163.65 million. During the same period in the prior year, the business posted $0.28 earnings per share. Repligen's revenue was up 10.4% compared to the same quarter last year. Equities research analysts anticipate that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Repligen

Several large investors have recently bought and sold shares of the company. Price T Rowe Associates Inc. MD increased its stake in Repligen by 6.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 7,566,093 shares of the biotechnology company's stock valued at $962,711,000 after purchasing an additional 430,039 shares in the last quarter. Vanguard Group Inc. increased its stake in Repligen by 1.1% in the fourth quarter. Vanguard Group Inc. now owns 5,101,090 shares of the biotechnology company's stock valued at $734,251,000 after purchasing an additional 56,723 shares in the last quarter. Champlain Investment Partners LLC increased its stake in Repligen by 8.6% in the fourth quarter. Champlain Investment Partners LLC now owns 1,543,530 shares of the biotechnology company's stock valued at $222,176,000 after purchasing an additional 122,595 shares in the last quarter. Alliancebernstein L.P. increased its stake in Repligen by 1.3% in the first quarter. Alliancebernstein L.P. now owns 1,024,180 shares of the biotechnology company's stock valued at $130,317,000 after purchasing an additional 13,284 shares in the last quarter. Finally, Conestoga Capital Advisors LLC increased its stake in Repligen by 3.4% in the first quarter. Conestoga Capital Advisors LLC now owns 980,247 shares of the biotechnology company's stock valued at $124,727,000 after purchasing an additional 32,665 shares in the last quarter. Institutional investors own 97.64% of the company's stock.

About Repligen

(Get Free Report)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Featured Articles

Should You Invest $1,000 in Repligen Right Now?

Before you consider Repligen, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.

While Repligen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Congress Bought This Stock at the Bottom—Will You Miss It?
The Drone Industry Is About to 10X—Here’s How to Profit
Why AMD Stock Beats NVIDIA Right Now

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines